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Significance of this study
What is already known on this subject?
 ► Precision medicine requires simple and 
accurate stratification of patients in advance of 
treatment decisions.
 ► The Wnt pathway can be activated either 
through constitutive activation of downstream 
signal transduction (ligand-independent 
(LI) mutation) or from the disruption of the 
synergistic R-Spondin axis (ligand-dependent 
(LD) mutation).
 ► Preclinical models of LD tumours retain 
therapeutic sensitivity to ligand inhibition, and 
small molecule Porcupine inhibitors are in early 
phase clinical trials.
What are the new findings?
 ► Wnt ligand-dependent and ligand-independent 
tumour subgroups exhibit non-overlapping 
transcriptional, epigenetic, morphological and 
clinical characteristics.
 ► We identify a rare tumour subset, termed 
RSPO-high with Wnt disruption predominantly 
driven by desmoplastic stromal expression of 
R-Spondin ligands.
 ► Differential expression of some Wnt negative 
regulator genes between tumour subgroups is 
associated with targeted promoter methylation 
in LD tumours.
 ► One of these differentially expressed 
negative regulators, AXIN2, can be used as 
a discriminatory molecular biomarker of LD 
tumours with an area under the curve >0.93.
ABSTRACT
Objective Pathological Wnt pathway activation is a 
conserved hallmark of colorectal cancer. Wnt-activating 
mutations can be divided into: i) ligand-independent (li) 
alterations in intracellular signal transduction proteins 
(Adenomatous polyposis coli, β-catenin), causing 
constitutive pathway activation and ii) ligand-dependent 
(lD) mutations affecting the synergistic r-Spondin axis 
(RNF43, RSPO-fusions) acting through amplification of 
endogenous Wnt signal transmembrane transduction. Our 
aim was to exploit differential Wnt target gene expression 
to generate a mutation-agnostic biomarker for lD tumours.
Design We undertook harmonised multi-omic analysis 
of discovery (n=684) and validation cohorts (n=578) of 
colorectal tumours collated from publicly available data 
and the Stratification in colorectal cancer consortium. 
We used mutation data to establish molecular ground 
truth and subdivide lesions into li/lD tumour subsets. We 
contrasted transcriptional, methylation, morphological 
and clinical characteristics between groups.
Results Wnt disrupting mutations were mutually 
exclusive. Desmoplastic stromal upregulation of RSPO 
may compensate for absence of epithelial mutation 
in a subset of stromal-rich tumours. Key Wnt negative 
regulator genes were differentially expressed between 
lD/li tumours, with targeted hypermethylation of some 
genes (AXIN2, NKD1) occurring even in ciMP-negative 
lD cancers. AXIN2 mrna expression was used as a 
discriminatory molecular biomarker to distinguish lD/li 
tumours (area under the curve >0.93).
Conclusions epigenetic suppression of appropriate Wnt 
negative feedback loops is selectively advantageous in lD 
tumours and differential AXIN2 expression in lD/li lesions 
can be exploited as a molecular biomarker. Distinguishing 
between lD/li tumour types is important; patients with 
lD tumours retain sensitivity to Wnt ligand inhibition and 
may be stratified at diagnosis to clinical trials of Porcupine 
inhibitors.
InTRODuCTIOn
The Wnt pathway is critical for intestinal devel-
opment and adult tissue cell fate determination.1 
Consistent with this key homeostatic role, epithelial 
Wnt signalling is strictly regulated, with activity 
predominantly restricted to the bottom half of the 
intestinal crypt where the adult intestinal stem cell 
niche and the proliferative transit amplifying cells 
are located.2
The canonical Wnt ligands are predominantly 
expressed by stem cell niche constituents including 
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Significance of this study
How might it impact on clinical practice in the foreseeable 
future?
 ► Currently, identification of solid tumour patient subgroups 
with LD mutations would require multi-omic analysis which is 
impractical for routine clinical use.
 ► Use of AXIN2 as a single gene, mutation-agnostic biomarker 
on diagnostic biopsies could help stratify patients that might 
benefit from Wnt ligand inhibition.
telocytes,3 Gli1+ve fibroblasts4 and Paneth cells.5 These para-
crine morphogens are secreted following palmitoylation by 
the membrane bound O-acyltransferase, Porcupine6 and this 
post-translational modification is required for activity of Wnt 
ligands. Wnt activation results from the binding of ligand to 
cognate Frizzled (FZD) and lipoprotein receptor-related protein 
receptors on the cell surface. Recently, the R-Spondin signalling 
pathway has emerged as a key, co-evolved pathway for Wnt 
amplification. In the absence of R-Spondin ligand, cell-surface 
Wnt FZD receptors are degraded by the activity of the E3 ubiq-
uitin ligases Ring finger protein 43 (RNF43) and Zinc and Ring 
Finger 3 (ZNRF3). Binding of secreted R-Spondin morphogens to 
transmembrane leucine-rich repeat-containing G protein coupled 
receptors 4–6 inhibits RNF43/ZNRF3, disinhibiting Fzd recep-
tors and powerfully amplifying Wnt signalling activity without 
affecting endogenous canonical Wnt ligand tone.7
The key intracellular signal transducer of the canonical Wnt 
pathway is β-catenin, encoded by Catenin-Beta1 (CTNNB1). In 
the absence of Wnt ligand, cytosolic β-catenin is targeted for 
degradation by a multi-protein destruction complex consisting of 
Adenomatous polyposis coli (APC), Axin-like protein (Axin 1/2), 
Glycogen synthase kinase (GSK3β) and Casein kinase (CK1α). 
Ligand-receptor binding blocks the activation of the destruction 
complex, releasing β-catenin which accumulates in the cytosol, 
translocates to the nucleus and forms a transcriptional complex, 
activating a large number of Wnt target genes.
In adult intestinal homeostasis, precise control over the polar-
ised gradient of Wnt signalling activity is vital to permit homeo-
static cell function, while avoiding the significant pathological 
consequences of disrupted Wnt activity. Autoregulatory control 
of the pathway is exerted by negative feedback loops and these 
control and fine-tune the physiological Wnt rheostat. These 
loops are rapidly activated following Wnt pathway stimulation, 
and act at multiple levels of the signalling cascade including: 
secreted antagonists (eg, secreted FZD-related proteins, ligand 
palmitoleoylate hydrolases, eg, Notum palmitoleoyl-protein 
carboxylesterase (NOTUM), receptor inhibitors, eg, Dickkopf-re-
lated protein (DKK), Adenomatosis polyposis coli downregulated 
1 (APCDD1) and signal transduction inhibitors, eg, AXIN1/2, 
Naked Cuticle 1 (NKD1)). Animal models show varying devel-
opmental and pathological consequences of Wnt inhibitor 
knockout, reflecting the context dependency of Wnt signalling 
function in different cell types.8 It is this evolved complexity of 
the Wnt regulatory network that permits context-dependent 
amplification or attenuation of Wnt signal activity.
Loss of control of this strictly regulated pathway is associated 
with pathology in many organs. In the intestine, pathological 
Wnt activation is a conserved hallmark of intestinal cancer with 
a spectrum of activating alterations seen in the vast majority of 
colorectal cancers (CRC).9 These include loss-of-function muta-
tions in APC and RNF43 and gain-of-function mutations in 
RSPO (characterised by gene fusions) and CTNNB1.9–11 While 
APC and CTNNB1 alterations drive downstream activation of 
the Wnt pathway that is independent of Wnt ligand binding 
(ligand-independent (LI)), RSPO and RNF43 alterations disrupt 
the synergistic R-Spondin axis and amplify endogenous Wnt 
ligand signalling (ligand-dependent (LD)). These mutations 
are almost always mutually exclusive in CRC, which is consis-
tent with previous work demonstrating that an optimal but not 
excessive level of Wnt activation is considered favourable for 
tumourigenesis—the ‘just-right’ theory.12
Interestingly, different Wnt pathway mutations are selectively 
and preferentially acquired in different polyp subtypes. Thus, 
conventional tubular and tubulovillous adenomas are charac-
terised by APC or, less commonly, CTNNB1 mutations while 
serrated polyps such as sessile serrated lesions (SSL) and tradi-
tional serrated adenomas (TSA) commonly select for RNF43 
mutation or RSPO fusions, suggesting that tumours with these 
mutations follow a distinct evolutionary trajectory.13 Proac-
tive molecular stratification of LD or LI Wnt driver mutations 
is potentially clinically important; tumours driven by LD Wnt 
driver mutations retain sensitivity to Wnt inhibition through 
Porcupine inhibitors or anti-RSPO antibodies.14 However, there 
is no simple biomarker available to identify the LD patient 
cohort which currently requires undertaking targeted panel/
exome sequencing, together with RNA sequencing for RSPO 
fusions. Here, we show that differential Wnt negative feed-
back target gene expression between LD and LI tumours can be 
exploited to generate a mutation-agnostic, simple, single molec-
ular biomarker to discriminate between tumours, and that this 
could be used clinically to identify patients with cancers that 
might be sensitive to preoperative Porcupine inhibitor therapy.
MeTHODS
Multi-omic profiling performed in each patient cohort is 
summarised in online supplementary table 1. See online supple-
mentary methods for details on data access, sample selection, 
nucleic acid extraction, quantitative real-time PCR (qRT-PCR), 
bioinformatic analyses, in situ hybridisation (ISH) and digital 
pathology.
ReSulTS
Cohort characteristics
As detailed in table 1.
Driver Wnt pathway alterations are mutually exclusive in 
colorectal polyps, colorectal tumours and non-colorectal 
tumours
To characterise the landscape of Wnt-altering events in CRC 
and other tumours, we undertook multi-omic analysis of cohorts 
from the Stratification in Colorectal Cancer (S:CORT) study 
and publicly available data (methods). The aim was to segregate 
tumours into two clusters: LI tumours with identifiable muta-
tions in APC or CTNNB1 and LD lesions with RSPO2/3 fusions 
or RNF43 alterations. APC, RNF43 and CTNNB1 mutations 
were identified by DNA sequencing. RSPO2 and RSPO3 gene 
fusions were identified by the presence of specific fusion break-
point sequences in RNA sequencing reads.
Discovery cohorts included a selected precancerous polyp 
cohort (n=54 from S:CORT), deliberately incorporating polyps 
from across the histological spectrum (clinicopathological 
features summarised in online supplementary table 2). Muta-
tional analysis identified activating Wnt alterations in 41/54 
polyps (76%) (figure 1A, online supplementary tables 3 and 
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Table 1 Cohort characteristics for the seven cohorts of samples included in this study
Cohort Origin Type Preparation Sample size Pathology Mean age M:F ratio
Discovery Polyps Internal (S:CORT) Biopsy Fresh/frozen n=54 Adenoma 67.0 1.00
A (DC-A) TCGA9 Resection Fresh/frozen n=618 Carcinoma (colon, rectum) 66.4 1.15
B (DC-B) Genentech11 Resection Fresh/frozen n=66 Carcinoma (colon) NA NA
Pancancer TCGA17 Resection Fresh/frozen n=10 542 Carcinoma (non-colorectal) 59.1 0.92
Validation A (Val-A) Internal (S:CORT) Resection FFPE n=348 Carcinoma (colon, rectum) 63.5 1.79
B (Val-B) Internal (S:CORT) Biopsy FFPE n=230 Carcinoma (rectum) 67 1.71
Clinical application Internal Resection FFPE n=63 Carcinoma (rectum) 70.4 1.63
FFPE, formalin-fixed paraffin embedded; NA, not available; S:CORT, Stratification in Colorectal Cancer.
4). The 13 lesions without detectable mutation were non-dys-
plastic SSLs—this is consistent with evidence that SSLs acquire 
Wnt alterations at an advanced stage, as part of progression to 
dysplasia.15 All Wnt alterations identified were mutually exclu-
sive. In line with previous findings,16 LD alterations were only 
identified in TSAs and SSLs, whereas LI alterations were seen 
across all histological polyp types.
We applied the same stringent mutational analysis to two CRC 
discovery cohorts (discovery cohort A from TCGA and discovery 
cohort B from Genentech) incorporating 684 colorectal tumours. 
Functionally relevant, activating Wnt alterations were identified 
in 431/684 (63%) tumours (figure 1A, online supplementary 
tables 3 and 4). In this large tumour cohort, we identified just 
14/431 (3%) tumours with more than one detectable Wnt driver 
alteration.
To assess the spectrum of Wnt drivers in tumours from other 
primary sites, we undertook mutational analysis across the 
TCGA pan-cancer cohort of 10 542 non-colorectal tumours17 
and identified Wnt mutations in 203/10 542 (2%) tumours 
(figure 1A, online supplementary tables 3 and 4). The most 
common primary sites for tumours with Wnt disrupting alter-
ations were endometrium, liver and stomach. Consistent with 
results in our colorectal cohorts, only 4/203 (2%) of non-CRC 
tumours contained more than one Wnt driver. Together, this 
mutual exclusivity suggests strong selection pressure against 
acquiring more than one Wnt driver mutation.
Stromal overexpression of R-Spondin as a novel driver 
alteration in colorectal cancer
To internally validate our fusion calling we determined 
normalised RSPO2/3 expression in samples with and without 
RSPO fusions. In the polyp cohort, we found that all polyps with 
outlier RSPO expression (defined as z-score ≥2) had detectable 
RSPO fusions (online supplementary figure 1). In contrast, in 
the discovery cohort, we identified a subset of tumours (termed 
RSPO-high, n=16/684) with outlier expression of RSPO2/3 
despite absence of detectable fusion mutation (online supple-
mentary figure 1). The majority of these samples (10/16) had 
no other identifiable Wnt alterations. Homeostatically, RSPO 
expression exclusively from muscularis mucosae fibroblasts 
maintains the intestinal crypt stem cell niche, so we reasoned that 
tumour microenvironmental RSPO expression could compen-
sate for the absence of epithelial Wnt mutations in RSPO-high 
tumours. Consistent with a stromal R-Spondin source, analysis 
of gene expression profiles in RSPO-high versus RSPO-fusion 
tumours showed that the former exhibit significant upregula-
tion of a validated cancer-associated fibroblast gene signature18 
(figure 1B, p=9.04×10−8), and that 10/12 RSPO-high tumours 
with available consensus molecular subtype (CMS) classifica-
tion were CMS4 (mesenchymal) subtype tumours (figure 1C). 
In addition, blinded expert histopathological review of digital 
slides identified trends towards increased tumour budding and 
reduced glandular formation in RSPO-high versus RSPO-fusion 
lesions (online supplementary figure 1B).
As these discovery sets were derived from publicly available 
datasets, we had no tissue access to check on-slide RSPO cell 
compartment expression. We therefore collated a cohort of 
tumours with available tissue sections derived from both a clinical 
application cohort of rectal tumours (n=63, table 1) and valida-
tion cohort A (n=348). Tumours with outlier RSPO3 expression 
were profiled using both targeted RSPO3 RNA sequencing to 
identify fusion genes and ISH to visualise the origin of the RSPO3 
signal in these samples. We identified six tumours with outlier 
RSPO3 expression, four of which had detectable RSPO3 fusions. 
The RSPO-fusion tumours exhibited a tissue compartmental shift 
in expression with epithelial localisation of transcripts, whereas 
RSPO-high tumours exhibited marked upregulation of RSPO3 
expression from the desmoplastic stroma (figure 1D, online 
supplementary figure 2). Finally, ISH on a subset of tumours 
with non-outlier RSPO3 expression (n=20) demonstrated quali-
tative correlation between expression and stromal staining, alto-
gether suggesting that RSPO3 stromal expression in RSPO-high 
tumours reflects an extreme perturbation of constitutive stromal 
RSPO3 expression (online supplementary figure 2).
In summary, RSPO-high tumours characterise a rare tumour 
subset, with Wnt disruption predominantly driven by desmo-
plastic stromal overexpression of R-Spondin ligands. We incor-
porated this subset of tumours in our LD cluster for further 
analysis. After including this RSPO-high cohort as potential LD 
tumours, the total number of tumours with detectable LD alter-
ations was 75/684 (11.3%).
Distinct regulation of endogenous Wnt negative feedback 
loops in ligand-dependent tumours
Having established the molecular ground truth, we segregated 
tumour samples in the discovery cohort into LD (RSPO-fu-
sions, RSPO-high and RNF43 mutations, n=64) and LI (APC 
or CTNNB1 mutations, n=347) subsets. Samples with concur-
rent LD and LI alterations (n=9) were excluded to minimise the 
potential for misclassification (figure 2A). In light of the specific 
polyp type predilection and mutual exclusivity of different Wnt 
mutations in colorectal tumourigenesis, we hypothesised that, 
rather than being interchangeable, LD and LI alterations drive 
distinct patterns of Wnt pathway activation. To assess this, we 
performed differential gene expression analysis between LD and 
LI lesions in our discovery cohorts (online supplementary figure 
3A) and undertook gene-set enrichment analysis, incorporating 
four curated subsets of Wnt target genes (global Wnt respon-
sive, stem cell, proliferative and negative regulator (NR) genes, 
detailed in online supplementary table 5). While there was no 
evidence of significant enrichment of global or proliferative 
Wnt targets in either cohort, there was significant enrichment 
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Figure 1 Wnt mutation burden and RSPO-high tumours. (A) Oncoprint of identifiable Wnt disrupting mutation distribution in the Stratification 
in Colorectal Cancer (S:CORT) polyp cohort, TCGA CRC cohort and TCGA solid cancer cohorts. Only tumours with detectable Wnt alterations are 
displayed. (B) Comparison of transcriptome-based cancer-associated fibroblast score in RSPO-fusion and RSPO-high tumours. (C) Consensus molecular 
subtype (CMS) of RSPO-high tumours. (D) RSPO3 in situ hybridisation (brown spots) exclusively from the muscularis mucosae in normal human colon, 
with aberrant epithelial expression in an RSPO3-fusion tumour and upregulated stromal expression in an RSPO3-high tumour.
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Figure 2 Differential expression of Wnt target genes. (A) Gene set enrichment analysis (GSEA) was performed on discovery cohort A (TCGA) to 
assess differential expression of i) Global Wnt responsive genes ii) Crypt base columnar stem cell Wnt targets iii) Proliferative cell Wnt targets iv) Wnt 
negative regulator genes, between ligand-independent (LI) and ligand-dependent (LD) tumours. (B) Gene expression of five leading edge negative 
regulator (NR) genes between LD and LI tumours in the combined discovery cohorts (log-CPM). NES, Normalised enrichment score.
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of NRs (normalised enrichment score (NES) >2.02, p<0.003) 
and to a lesser extent, stem cell targets (NES >1.53, p<0.04) in 
LI tumours (figure 2A, online supplementary figure 3B). Anal-
ysis of leading-edge genes within the NR signature identified 
five consensus differentially expressed NRs in the two discovery 
cohorts, all expressed at a significantly higher level in LI versus 
LD tumours—AXIN2, NKD1, APCDD1, NOTUM and DKK4 
(figure 2B).
Hypermethylation of endogenous negative regulators in 
ligand-dependent tumours
Previous studies have identified evidence of hypermethylation 
of Wnt NRs, such as AXIN2 and DKK1, in serrated lesions.19 
As a result, we hypothesised that differential expression of Wnt 
NRs could be driven by differential methylation. To investigate 
this, we undertook methylation analysis of tumours in discovery 
cohort A (n=440)—the only discovery cohort with available 
methylation data. We identified 26 differentially methylated 
probes (DMPs) annotated to four of the five differentially 
expressed Wnt NR genes (AXIN2, NKD1, APCDD1, NOTUM) 
(online supplementary table 6); 25/26 of these probes were 
significantly hypermethylated (online supplementary table 6), 
with significantly elevated mean beta values for each of the four 
NR genes in LD versus LI tumours (figure 3A, online supple-
mentary figure 4). To understand whether this signal was derived 
entirely from aberrant methylation in CpG island methylator 
phenotype (CIMP) tumours, we determined mean beta value for 
each NR in both CIMP+ve and CIMP−ve LD and LI tumour 
subsets. Interestingly, while hypermethylation of NOTUM and 
APCDD1 was associated with CIMP positivity (online supple-
mentary figure 4), there was no significant difference in meth-
ylation of AXIN2 and NKD1 between CIMP+ve and CIMP−ve 
tumours, indicating CIMP-independent selective methylation 
of these genes (figure 3B). Consistent with a functional impact 
of hypermethylation, AXIN2 and NKD1 exhibit significant and 
near-linear anticorrelation between methylation and normalised 
gene expression (figure 3C, r=−0.68 and r=−0.72 respec-
tively, online supplementary table 7). In contrast, NOTUM and 
APCDD1 exhibit a bimodal distribution of methylation beta 
value, implicating a role for alternative regulatory mechanisms 
(online supplementary figure 4). Together these data suggest 
that hypermethylation of endogenous Wnt NRs, especially 
AXIN2 and NKD1, may act in a synergistic fashion with LD Wnt 
disrupting mutations.
Application of AXIn2 as a clinical biomarker for ligand-
dependent tumours
Having demonstrated consistent, differential expression of Wnt 
NRs, we hypothesised that we could exploit these discrimina-
tory differences to identify and validate a simple, mutation-ag-
nostic biomarker to identify patients with LD tumours that 
could potentially benefit from Porcupine inhibition. First, we 
applied receiver operating characteristic (ROC) curve analysis 
to the LD (n=64) and LI (n=347) subsets within the discovery 
cohort to determine the diagnostic utility of each consensus NR 
(online supplementary table 8). This analysis showed that AXIN2 
demonstrated superior diagnostic performance with area under 
the curve (AUC) of 0.93 (95% CI 0.89 to 0.97, figure 4A). Using 
an AXIN2 expression threshold to maximise the sum of sensi-
tivity and specificity, this translated to sensitivity and specificity 
of 94.5% and 78.5%, respectively (threshold=5.75 log-counts 
per million/CPM).
Next, to validate the accuracy of AXIN2 as a feasible biomarker 
for identification of LD tumours, we turned to two validation 
cohorts (Val-A/Val-B) derived from the S:CORT study (table 1). 
Using molecular ground truth data, each cohort was stratified 
into three subsets: LD, LI or unclassified (termed excluded (EX), 
figure 4B,C). In both cohorts, differential AXIN2 expression was 
discriminatory between LD and LI tumours while EX tumours 
exhibited variable AXIN2 expression (figure 4B,C). ROC curve 
analysis in these validation sets confirmed the LD/LI discrimi-
natory capacity of AXIN2 expression with AUC of 0.95 (95% 
CI 0.89 to 1.00) in Val-A (figure 4B) and 0.97 (95% CI 0.93 to 
1.00) in Val-B (figure 4C). Using an AXIN2 expression threshold 
to maximise the sum of sensitivity and specificity, this trans-
lated to sensitivity and specificity of 92.2% and 90.4% in Val-A 
(threshold=5.58 log-arbitrary units) and 86.1% and 100% in 
Val-B (threshold=5.57 log-arbitrary units).
To further evaluate AXIN2 as a tumour biomarker, we wanted 
to assess both qRT-PCR and immunohistochemistry (IHC) as 
alternative approaches for scoring AXIN2 expression in a real-
istic clinical setting. We extracted RNA from one formalin-fixed 
paraffin embedded (FFPE) section per lesion from our clinical 
application cohort (n=63), and immunohistochemically stained 
a subsequent section for AXIN2 protein. RNA was assayed using 
both 3’RNA-sequencing and qRT-PCR using the Fluidigm plat-
form. In our hands, only 31/63 of these FFPE samples passed 
stringent quality control for 3’RNA-sequencing (aligned reads 
>75%) in contrast to 62/63 samples for qRT-PCR. There was 
robust correlation between AXIN2 scored by qRT-PCR and 
3’RNA-sequencing (n=31, r=0.75, p=1.73×10−6, online 
supplementary figure 5). Next, we scored AXIN2 IHC staining on 
available sections (n=53) using two complementary approaches: 
automated scoring using the HALO digital pathology platform 
and manual scoring by expert histopathologist in a random 
subset of tumours (n=27). Across the cohort, we identified weak 
correlation between qRT-PCR metrics of AXIN2 mRNA expres-
sion and manual scores of AXIN2 IHC (r=0.35, p=0.077, 
online supplementary figure 5), while there was no significant 
correlation with automated scores of AXIN2 IHC (p>0.29). 
However, the four tumours with known LD status (RSPO-fusion 
n=3, RSPO-high n=1) had comparably low manually scored 
AXIN2 protein expression (online supplementary figure 5). In 
summary, qRT-PCR for AXIN2 is a feasible approach to assay 
AXIN2 expression in a situation of limited tissue availability, 
while IHC staining is insufficiently sensitive to consistently 
reflect differences in AXIN2 transcriptome expression.
ligand-dependent disease positioning in colorectal cancer
In light of evidence that LD tumours derive from distinct 
precursor lesions and have different Wnt pathway dynamics, we 
hypothesised that there would be conserved clinicopathological 
differences between LD and LI tumours, and detectable differ-
ences between subsets with distinct LD alterations. To investigate 
this, we pooled tumours with available clinicopathological anno-
tations (discovery cohort A and validation cohort A, n=635). 
We then contrasted demographics (age, sex, tumour location), 
molecular pathology (BRAF/KRAS mutation status, microsatel-
lite instability, CMS subtype), computationally scored histopa-
thology (mucin, stroma, tumour and glandular area per slide) 
and prognostic (overall survival, disease-free survival (DFS)) 
metrics for each subtype.
In comparison to LD tumours, LI tumours were significantly 
enriched for left-sided tumours (sigmoid and rectum), KRAS 
mutations and CMS2 (canonical) classification, consistent with 
copyright.
 o
n
 O
ctober 8, 2019 at Barnes Library M
edical School. Protected by
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2019-319126 on 28 September 2019. Downloaded from 
7Kleeman SO, et al. Gut 2019;0:1–12. doi:10.1136/gutjnl-2019-319126
GI cancer
Figure 3 Methylation of key negative regulator genes. (A) Methylation (mean beta value) of AXIN2 and NKD1 showing differential methylation 
of Wnt NR genes between LD and LI tumours. (B) Methylation (mean beta value) of AXIN2 and NKD1 shows no significant difference between CpG 
island methylator phenotype (CIMP) positive (blue), and negative (red) LD and LI tumours. (C) Significant anticorrelation between AXIN2 and NKD1 
normalised gene expression (log-counts per million/CPM) and gene methylation (mean beta value). All data from discovery cohort A (TCGA).
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Figure 4 AXIN2 as a clinically discriminatory biomarker. (A) Combined discovery cohorts (TCGA and Genentech). (B) Validation cohort A (S:CORT). 
(C) Validation cohort B (S:CORT). i) Flow diagram showing exclusion criteria. ii) Differential AXIN2 mRNA expression between LD and LI tumours. 
iii) Receiver operating characteristic (ROC) curve to assess diagnostic performance of AXIN2 expression. AXIN2 thresholds shown by red lines in 
combined discovery cohorts, validation cohort A and validation B were 5.75 log-CPM, 5.58 log-arbitrary units and 5.57 log-arbitrary units respectively.
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conventional lesion molecular pathway (figure 5A,B, online 
supplementary table 9). Analysis of prognostic data identi-
fied a non-significant trend towards worse DFS in LI tumours 
(HR=1.42, p=0.0594). LD tumours were also substratified 
into RSPO-fusion, RSPO-high and RNF43-mutant subsets. 
To minimise misclassification of tumours, samples with both 
outlier RSPO2/3 expression and RNF43 mutations (n=6) were 
excluded leaving a total of 68 tumours. RNF43-mutant tumours 
were significantly enriched for right colonic distribution, BRAF 
mutations, microsatellite instability and CMS1 (MSI immune) 
classification, consistent with predominantly sessile serrated 
lesion aetiology (online supplementary table 10). Conversely, 
50% of RSPO-fusion tumours were located distal to the sigmoid, 
with a lower frequency of CMS1, suggesting enrichment of 
tumours progressing from traditional serrated adenoma precur-
sors (online supplementary figure 5C).
Unexpectedly, using automated segmentation of available 
scanned tumour sections (n=194) we found that computation-
ally scored mucin area was significantly increased in LD tumours 
(p=2.02×10−5, figure 5C). To validate this finding, we extracted 
published20 manually scored mucin area data for a subset of 
tumours in DC-A (n=246) and confirmed this metric is also 
markedly increased in LD tumours (p=2.40×10−5, figure 5D). 
To assess the degree to which mucin area can distinguish between 
LD and LI tumours, we performed ROC curve analysis for each 
mucin metric. This demonstrated AUC of 0.78 (95% CI 0.70 to 
0.85) for computationally scored mucin and AUC of 0.75 (95% 
CI 0.66 to 0.83) for manually scored mucin.
DISCuSSIOn
The ability to segregate colorectal tumour patients into clinically 
meaningful subsets is important to identify patients suitable for 
targeted therapies and allows comparison and correlation of 
molecular, morphological and clinical phenotypes. Wnt pathway 
disruption through selected (epi)genetic mutation is an obli-
gate requirement in almost all CRCs and is common in many 
other types of solid tumours. However, accurate stratification 
of patients and successful therapeutic manipulation of patho-
logical Wnt signalling has proven challenging. The majority of 
colorectal tumours are Wnt ligand-independent, activating the 
pathway constitutively, through mutation of the intracellular 
signal transduction machinery. However, a significant subset 
select for epithelial mutations affecting the synergistic R-Spondin 
axis, rendering them sensitive to therapeutic manipulation of 
canonical ligand expression. Here, we have also identified a 
small, but potentially interesting cohort of tumours that lack 
epithelial Wnt driver mutations altogether—instead profoundly 
upregulating R-Spondin signalling from the tumour stroma. This 
suggests that stromal compartment expression of Wnt ligands 
can compensate for absence of selected epithelial mutation in 
these predominantly aggressive, mesenchymal-subtype (CMS4), 
‘RSPO-high’ tumours. To identify patients with convergent 
epithelial or stromal LD Wnt disruption, we demonstrate vari-
able expression of Wnt responsive genes in CRC subsets, and 
use this to highlight differential AXIN2 expression as a simple, 
discriminatory and mutation-agnostic molecular biomarker.
The mutual exclusivity of LD and LI mutations suggests that 
activation of either the R-Spondin or downstream canonical axis 
of Wnt signalling alone is sufficient for tumourigenesis. Multiple 
Wnt driver mutations result in excessive Wnt disruption and are 
selected against the ‘just-right’ hypothesis. However, despite this 
mutual exclusivity, Wnt disrupting mutations are not necessarily 
equivalent with respect to downstream target gene activation, 
with differences in Wnt responsive gene enrichment between 
LD and LI tumours. The Wnt responsive gene set that showed 
maximal divergence was ‘NRs’, with five significantly differ-
entially expressed genes between LD and LI tumours. These 
important autoregulatory genes are rapidly responsive to Wnt 
stimulation and act in parallel, at multiple pathway levels to 
control the intensity and/or duration of the signal. Expression 
divergence in these tumour subsets may be partly explained by 
epigenetic regulation, with hypermethylation of NRs in some 
LD tumours. Gene methylation correlates with low transcript 
expression, and Aza-C demethylation treatment restores AXIN2 
expression in a dose-dependent fashion in CRC cell lines.21 Inter-
estingly, epigenetic suppression of two key Wnt NRs (AXIN2, 
NKD1) in LD tumours can occur independently of the CpG 
island methylator phenotype, where promoter methylation is 
globally dysregulated.22 This suggests that targeted, rather than 
stochastic methylation of Wnt regulatory genes may occur in 
these lesions. This is biologically plausible. Wnt activation in LD 
tumours is the consequence of increased flux through an other-
wise intact intracellular signalling pathway. Physiologically rele-
vant and functioning negative feedback loops would constrain 
pathological LD Wnt signalling, so epigenetic downregulation of 
involved NR genes would be advantageous in lesions progressing 
down a LD molecular pathway. In contrast, the constitutive, intra-
cellular activation of Wnt signalling through APC or CTNNB1 
mutation in LI tumours, renders upstream Wnt NRs functionally 
redundant and uncouples appropriate feedback loop equilibrium 
(figure 6). The mechanistic explanation for these observations 
needs further detailed functional research, but the differential 
methylation and expression of key Wnt target genes across the 
spectrum of LD and LI tumours should be considered when 
using genes like AXIN2 as a surrogate measure of global Wnt 
activation.
LD tumours retain sensitivity to Wnt ligand inhibition 
with Porcupine inhibitor14 or anti-RSPO3 antibody therapy23 
resulting in regression and differentiation of human RSPO-fu-
sion tumours in patient-derived xenograft models. Our anal-
ysis across tumour types has detected LD Wnt alterations in 
colorectal (10%), stomach (2%), endometrial (1%) and pancreas 
(1%) tumours while recent work has identified a subset of hepa-
tocellular carcinomas (1%) with RSPO2 gene fusions.24 Detec-
tion of these alterations at diagnosis might allow these patients 
to benefit from chemotherapeutic Wnt ligand suppression. 
Using current techniques, LD tumour discrimination requires 
genetic and transcriptomic analysis of all tumours to identify 
Wnt disrupting mutations and RSPO-fusion transcripts. This is 
impractical for routine diagnostic assessment. We have exploited 
the differential expression of Wnt responsive genes across the 
tumour spectrum to identify a molecular biomarker that discrim-
inates LD/LI lesions at the target gene level. AXIN2 was the most 
discriminant single biomarker, with AUC for mRNA expres-
sion >0.93 in three independent cohorts. Quantitative assess-
ment of AXIN2 mRNA expression was unaffected by the type of 
sequencing technique (PolyA RNA seq, 3’RNA seq or qRT-PCR), 
and could be assessed with high discriminatory yield from diag-
nostic endoscopic biopsy samples in a validation cohort. This 
supports potential clinical application of the biomarker to stratify 
patients from endoscopic samples at the point of diagnosis, and 
in advance of treatment decisions. There was limited correlation 
between differential RNA expression and the heterogenous IHC 
staining of AXIN2 protein in our clinical application samples. 
This may be related to tissue processing variability or antibody 
insensitivity but known post-translational regulation and altered 
degradation of AXIN2 protein could also contribute.25 This 
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Figure 5 Clinical disease positioning of ligand-dependent and independent tumours. (A) Colonic distribution proportion of ligand-dependent (LD) 
(red line) and ligand-independent (LI) (blue line) tumours. (B) Consensus molecular subtype (CMS) of LD and LI tumours. (C) Representative images 
from digital pathology supervised image segmentation of invasive cancer into tissue compartments. (D) Manual and computational scoring of mucin 
area in LD and LI tumours segregated by molecular ground truth data.
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Figure 6 Model of Wnt negative regulation in ligand-dependent 
(LD) and ligand-independent (LI) tumours. In LD tumours, mutations 
in the synergistic RSPO axis upregulate Wnt signalling through an 
otherwise intact canonical Wnt signalling pathway. In this situation, 
appropriate upregulation of Wnt NRs (blue shapes) could restrain 
pathological Wnt pathway activity which generates a selective pressure 
for targeted methylation and epigenetic suppression of key Wnt NR 
activity (red borders). In LI tumours, downstream mutation in APC and 
CTNNB1 causes constitutive activation of Wnt intracellular signalling 
pathways rendering Wnt negative feedback functionally redundant and 
disconnecting the physiological negative regulator equilibrium.
precludes the use of IHC staining assessment as a standard diag-
nostic tool to identify LD patient subgroups.
Across the tumour cohorts in this study, there was a large number 
of lesions without identifiable Wnt disrupting alterations. This may 
result partly from missed mutations in retrospective data sets, for 
example, RNF43 hotspot mutations can be difficult to capture 
as they are susceptible to microsatellite loci slippage. However, 
this does not exclude the possibility of rare, novel epithelial (epi)
genetic Wnt drivers, or a cell-extrinsic, microenvironmental Wnt 
source—as seen in RSPO-high lesions. The range of AXIN2 expres-
sion seen in the EX lesions here, suggests that AXIN2 could be used 
to direct the search towards new LD or LI drivers.
Wnt signalling has remained difficult to target in solid tumours, 
because of developmental and homeostatic importance, pathway 
complexity and the frequency of non-actionable, signal transduction 
mutations. Although uncommon, LD tumours represent an oppor-
tunity for therapeutic Wnt inhibition and effective small molecule 
inhibitors are in phase I trials for a range of solid malignancies.26 
Precision targeted therapies rely on detection of suitable and distinct 
patient cohorts. Here, we have demonstrated molecular and pheno-
typic distinction between Wnt disrupted CRC tumour populations 
and exploited differential Wnt target expression to generate a simple, 
transcriptome-based biomarker to identify patients with LD tumours 
for entry into stratified medicine clinical trials.
Author affiliations
1intestinal Stem cell Biology lab, Wellcome trust centre Human genetics, University 
of Oxford, Oxford, UK
2Department of Pathology and Molecular Pathology, University Hospital Zürich, 
Zurich, Switzerland
3Oxford colorectal Surgery Department, nuffield Department of Surgery, churchill 
Hospital, Oxford, Oxfordshire, UK
4translational gastroenterology Unit, John radcliffe Hospital, Oxford, UK
5cancer genetics and evolution laboratory, institute of cancer and genomic 
Sciences, University of Birmingham, Birmingham, West Midlands, UK
6Department of Oncology, University of Oxford, Oxford, Oxfordshire, UK
7Surgical research laboratory, institute of cancer & genomic Science, University of 
Birmingham, Birminghaam, United Kingdom
8centre for cancer research and cell Biology, Queen’s University Belfast, Belfast, 
northern ireland, UK
9changi general Hospital, Singapore, Singapore
10South australian Health & Medical research institute & School of Medicine, the 
University of adelaide, adelaide, South australia, australia
Acknowledgements the authors would like to thank graeme Murray for provision 
of the rectal cancer biopsies under licence from the grampian biorepository, to 
Matt Seymour for use of the FOcUS trial samples and to the Mrc FOcUS trial 
management group.
Contributors SOK, VHK, tM and SJl conceived and designed the project. 
experiments were conducted by SOK, VHK, HJSJ, egV, HD, VP, MaJK, trMl, SlW and 
DW. Data provision and bioinformatic analysis were carried out by aDB, SOK, ra and 
eD. Pathology support, tissue provision and intellectual input were from VHK, l-MW, 
Jee, cc, MBl, PDD and it. Manuscript written by SOK and SJl.
Funding this work was supported by Wellcome trust Senior clinical research 
Fellowship (206314/Z/17/Z) and Worldwide cancer research grant (16-0042) to 
SJl, the Stratification in colorectal cancer (S:cOrt) consortium, which is funded by 
the Medical research council and cancer research UK and the national institute 
for Health research (niHr) Oxford Biomedical research centre. VHK was funded by 
the Swiss national Science Foundation (P2SKP3_168322/1 and P2SKP3_168322/2). 
HJSJ was supported by a Bowel Disease research Foundation (BDrF) research 
grant. aDB is funded by a cancer research UK advanced clinician Scientist award 
(c31641/a23923) and the Wellcome trust (102732/Z/13/Z). trMl, SlW and DW 
supported by the nHMrc, Beat cancer Sa & cure cancer australia. Jee was funded 
by the national institute for Health research (niHr) Oxford Biomedical research 
centre (Brc). core funding to the Wellcome trust centre for Human genetics was 
provided by the Wellcome trust (090532/Z/09/Z).
Competing interests SJl has received grant income from UcB Pharma. VHK is 
participant of a patent application co-owned by the netherlands cancer institute 
(nKi-aVl) and the University of Basel on the assessment of cancer immunotherapy 
biomarkers by digital pathology and has served as an invited speaker on behalf of 
indica labs. aDB has received grant funding from incyte for molecular pathology 
research; speaker fees and travel costs from illumina UK for immuno-oncology 
research and consultancy fees from Bristol-Myers-Squibb for immuno-oncology 
research. all other authors have nothing to disclose.
Patient consent for publication not required.
Provenance and peer review not commissioned; externally peer reviewed.
Data availability statement Data relating to transcriptome profiling of relevant 
genes in polyps cohort and validation cohorts a/B are available online (https://
www. s- cort. org/ exploiting- differential- wnt). all other data relevant to the study are 
referenced, included in the article or uploaded as supplementary information.
Open access this is an open access article distributed in accordance with the 
creative commons attribution 4.0 Unported (cc BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
ORCID iDs
Sam O Kleeman http:// orcid. org/ 0000- 0003- 1720- 8804
Hayley Davis http:// orcid. org/ 0000- 0003- 2914- 4932
copyright.
 o
n
 O
ctober 8, 2019 at Barnes Library M
edical School. Protected by
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2019-319126 on 28 September 2019. Downloaded from 
12 Kleeman SO, et al. Gut 2019;0:1–12. doi:10.1136/gutjnl-2019-319126
GI cancer
andrew D Beggs http:// orcid. org/ 0000- 0003- 0784- 2967
Susan l Woods http:// orcid. org/ 0000- 0002- 8955- 2017
ian tomlinson http:// orcid. org/ 0000- 0003- 3037- 1470
Philip D Dunne http:// orcid. org/ 0000- 0001- 9160- 283X
RefeRences
 1 Scoville DH, Sato t, He Xc, et al. current view: intestinal stem cells and signaling. 
Gastroenterology 2008;134:849–64.
 2 Mah at, Yan KS, Kuo cJ. Wnt pathway regulation of intestinal stem cells. J Physiol 
2016;594:4837–47.
 3 Shoshkes-carmel M, Wang YJ, Wangensteen KJ, et al. Subepithelial telocytes are an 
important source of Wnts that supports intestinal crypts. Nature 2018;557:242–6.
 4 Degirmenci B, Valenta t, Dimitrieva S, et al. gli1-expressing mesenchymal cells form 
the essential Wnt-secreting niche for colon stem cells. Nature 2018;558:449–53.
 5 Farin HF, Jordens i, Mosa MH, et al. Visualization of a short-range Wnt gradient in the 
intestinal stem-cell niche. Nature 2016;530:340–3.
 6 takada r, Satomi Y, Kurata t, et al. Monounsaturated fatty acid modification of Wnt 
protein: its role in Wnt secretion. Dev Cell 2006;11:791–801.
 7 Yan KS, Janda cY, chang J, et al. non-equivalence of Wnt and r-spondin ligands 
during lgr5+ intestinal stem-cell self-renewal. Nature 2017;545:238–42.
 8 Filipovich a, gehrke i, Poll-Wolbeck SJ, et al. Physiological inhibitors of Wnt signaling. 
Eur J Haematol 2011;86:453–65.
 9 cancer genome atlas network. comprehensive molecular characterization of human 
colon and rectal cancer. Nature 2012;487:330–7.
 10 giannakis M, Hodis e, Jasmine Mu X, et al. rnF43 is frequently mutated in colorectal 
and endometrial cancers. Nat Genet 2014;46:1264–6.
 11 Seshagiri S, Stawiski eW, Durinck S, et al. recurrent r-spondin fusions in colon cancer. 
Nature 2012;488:660–4.
 12 lamlum H, ilyas M, rowan a, et al. the type of somatic mutation at aPc in familial 
adenomatous polyposis is determined by the site of the germline mutation: a new 
facet to Knudson’s ’two-hit’ hypothesis. Nat Med 1999;5:1071–5.
 13 Sekine S, Yamashita S, tanabe t, et al. Frequent PtPrK-rSPO3 fusions and rnF43 
mutations in colorectal traditional serrated adenoma. J Pathol 2016;239:133–8.
 14 Madan B, Ke Z, Harmston n, et al. Wnt addiction of genetically defined cancers 
reversed by POrcn inhibition. Oncogene 2016;35:2197–207.
 15 Hashimoto t, Yamashita S, Yoshida H, et al. Wnt pathway gene mutations are 
associated with the presence of dysplasia in colorectal sessile serrated adenoma/
polyps. Am J Surg Pathol 2017;41:1188–97.
 16 Sekine S, Ogawa r, Hashimoto t, et al. comprehensive characterization of rSPO 
fusions in colorectal traditional serrated adenomas. Histopathology 2017;71:601–9.
 17 Hoadley Ka, Yau c, Hinoue t, et al. cell-of-origin patterns dominate the molecular 
classification of 10,000 tumors from 33 types of cancer. Cell 2018;173:291–304.
 18 isella c, terrasi a, Bellomo Se, et al. Stromal contribution to the colorectal cancer 
transcriptome. Nat Genet 2015;47:312–9.
 19 Muto Y, Maeda t, Suzuki K, et al. Dna methylation alterations of aXin2 in serrated 
adenomas and colon carcinomas with microsatellite instability. BMC Cancer 
2014;14:466.
 20 grasso cS, giannakis M, Wells DK, et al. genetic mechanisms of immune evasion in 
colorectal cancer. Cancer Discov 2018;8:730–49.
 21 Koinuma K, Yamashita Y, liu W, et al. epigenetic silencing of aXin2 in colorectal 
carcinoma with microsatellite instability. Oncogene 2006;25:139–46.
 22 toyota M, ahuja n, Ohe-toyota M, et al. cpg island methylator phenotype in 
colorectal cancer. Proc Natl Acad Sci U S A 1999;96:8681–6.
 23 Storm ee, Durinck S, de Sousa e Melo F, et al. targeting PtPrK-rSPO3 colon tumours 
promotes differentiation and loss of stem-cell function. Nature 2016;529:97–100.
 24 longerich t, endris V, neumann O, et al. RSPO2 gene rearrangement: a powerful driver 
of β-catenin activation in liver tumours. Gut 2019;68:1287–96.
 25 gao c, Xiao g, Hu J. regulation of Wnt/β-catenin signaling by posttranslational 
modifications. Cell Biosci 2014;4.
 26  clinicaltrials. gov. Study to evaluate the safety and tolerability of rXc004 in advanced 
malignancies. available: https:// clinicaltrials. gov/ ct2/ show/ nct03447470 [accessed 
17 May 2018].
copyright.
 o
n
 O
ctober 8, 2019 at Barnes Library M
edical School. Protected by
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2019-319126 on 28 September 2019. Downloaded from 
